TACE treatment of liver cancer can cause anoxic environment, induced VEGF expression, and neovascularization, while TACE combined with sorafenib to treat liver cancer can effectively inhibit regenerating blood vessels, reduce tumor recurrence and metastasis, and improve the therapeutic effect. This evidence concerns the gene VEGFA and liver cancer.